Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	38197
Country	United States

Received	2018-02-05 08:14
Peer-Review Started	2018-02-07 02:52
To Make the First Decision	2018-03-02 00:38
Return for Revision	2018-03-08 01:21
Revised	2018-03-14 03:42
Second Decision	2018-04-10 05:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-04-11 16:57
Articles in Press	2018-04-11 16:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-05-08 05:43
Publish the Manuscript Online	2018-05-15 07:28

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Merly Contratto and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words	Sequencing treatment; Sorafenib; Hepatocellular carcinoma treatments; Nivolumab; Regorafenib; Lenvatinib; Cabozantinib; Immunotherapy; Biomarker; Pembrolizumab; Ramucirumab; Alpha-fetoprotein; Neoantigen; Tumor mutational burden; Interferon-gamma
Core Tip	Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. There are some potential treatment options for first and second line HCC, there are also new biomarkers that can predict benefits from treatments such as immune checkpoint inhibitors.
Publish Date	2018-05-15 07:28
Citation	Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114
URL	http://www.wjgnet.com/1948-5204/full/v10/i5/108.htm
DOI	http://dx.doi.org/10.4251/wjgo.v10.i5.108

Full Article (PDF)	WJGO-10-108.pdf
Full Article (Word)	WJGO-10-108.doc
Manuscript File	38197-Review.docx
Answering Reviewers	38197-Answering reviewers.pdf
Audio Core Tip	38197-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	38197-Conflict-of-interest statement.pdf
Copyright License Agreement	38197-Copyright assignment.pdf
Peer-review Report	38197-Peer-review(s).pdf
Scientific Editor Work List	38197-Scientific editor work list.pdf